Novartis unveils new centered technique, underpinned by eight potential multi-billion greenback peak gross sales manufacturers & deep pipeline, at Meet the Administration occasion

• Transformation to pure-play Modern Medicines firm nears completion

• Focusing technique on 5 core Therapeutic Areas, key know-how platforms, and the US

• Advancing eight in-market manufacturers with multi-billion greenback peak gross sales potential and prioritizing pipeline to give attention to high-value NMEs

• Persevering with to ship rising gross sales, Core Op Inc, and money flows with constant shareholder pleasant capital allocation

Basel, September 22, 2022 — Novartis executives are assembly buyers and trade analysts in Basel right this moment, sharing insights into the up to date firm technique on the annual Meet Novartis Administration occasion. The assembly will enable contributors to be taught extra about Novartis journey to unite know-how management in Analysis and Improvement with novel entry approaches, serving to to alleviate a few of society’s biggest illness burdens.

“Novartis is reworking right into a ‘pure-play’ Modern Medicines firm. Our technique is targeted on 5 core enticing therapeutic areas, key know-how platforms, and the US market, with the intention to extend worth per new molecular entity from our deep pipeline”, mentioned Vas Narasimhan, CEO of Novartis. “We are going to proceed to ship improved financials with +4% gross sales CAGR by means of 2027 and a Core Op Inc margin ~40%+ within the mid – long run. Our disciplined capital allocation will steadiness continued funding within the enterprise and returning capital to our shareholders”.

Novartis is implementing this technique with a transparent give attention to 5 therapeutic areas for funding – cardiovascular, immunology, neuroscience, strong tumors and hematology. Novartis has a number of vital in-market and pipeline belongings in every of those areas, which symbolize vital illness burden and have the biggest progress potential within the USD 1 Tn innovatives medicines market. Eight present in-market manufacturers, Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix, every maintain multi-billion greenback peak gross sales potential.

Give attention to US and different precedence geographies together with China, Germany, Japan
These eight manufacturers are underpinning progress throughout all key geographies, supporting Novartis aspiration to enhance aggressive positioning and organically construct its US enterprise to develop into a top-five participant within the US by 2027. A ‘US-first’ mindset, rising share of US sufferers in medical trials and constructing functionality and expertise, amongst different actions, will allow Novartis to acheive this goal. Novartis additionally goals to be a top-three participant in China, a key progress marketplace for the following decade, whereas sustaining main positions in Germany and Japan.

Establishing Management throughout Key Expertise Platforms
The Novartis portfolio of medicines is shifting towards biologics and know-how platforms – recognizing their rising energy in tackling illness. Along with two established platforms in chemistry and biotherapeutics, three newer platforms – gene & cell remedy, radioligand remedy, and ‘xRNA’ – are being prioritized for continued funding into new R&D capabilities and manufacturing scale. With over 50 tasks in exploratory to early medical growth, Novartis is properly positioned to guide the trade in creating these platforms and develop our enterprise presence.

Wealthy Improvement Pipeline shifting to Excessive-Worth NMEs
Administration outlined its method to prioritization of Novartis wealthy pipeline. Rising industrial focus in 5 core remedy areas, in addition to renewed consideration to high-value belongings which have the potential to drive progress within the US, had been highlighted. The corporate showcased a lot of catalysts set to drive newsflow within the mid & near-term:

• Kisqali (ribociclib);information from the NATALEE trial in adjuvant HER2-negative breast most cancers in each high- and intermediate-risk sufferers with breast most cancers in 2023.
• Iptacopan; first part 3 trial leads to sufferers with paroxysmal nocturnal hemoglobinuria later this 12 months with extra information readouts in different indications in 2023.
• Pluvicto; part 3 information from the PSMAfore trial in metastatic castration-resistant prostate most cancers late 2022/early 2023.
• Remibrutinib; part 3 information from two trials in power spontaneous urticaria in 2024 and from two part 3 trials in relapsing a number of sclerosis in 2025.
• Scemblix (asciminib);information from the CML-CP trial in first line CML in 2024.

The excessive worth late stage growth pipeline can also be anticipated to ship a big quantity information readouts within the 2024-25 timeframe. Centered on driving operational excellence, Novartis shared insights into chosen early medical applications the place strengthening integration inside R&D will assist speed up growth and launch operational effectivity.

Persevering with to ship improved financials
The rising enterprise, with gross sales anticipated to enhance +4% CAGR 2021-2027, coupled with introduced strategic strikes, will allow enhancing monetary efficiency within the coming years. Core working revenue margin is predicted to extend to ~40+% within the mid – long run, together with the absorption of company prices. This improved profitability is ready to drive improved Free Money Circulate and Return on Invested Capital (ROIC).
Administration outlined Novartis disciplined shareholder-focused method to capital allocation, highlighting USD 53bn distributed to shareholders from 2017-2021. Substantial money era will proceed to permit us to steadiness returning capital to shareholders with investing within the enterprise.

Separation of Sandoz, by way of 100% spin-off, is in one of the best pursuits of shareholders
The Sandoz spin-off transaction is predicted to be accomplished in H2 2023, supporting Novartis ambitions in turning into a totally centered medicines firm. Sandoz is deliberate to be integrated in Switzerland and to be listed on the SIX Swiss Change, with an American Depositary Receipt (ADR) program within the US, and anticipated to develop into the publicly traded #1 European generics firm¹ and a world chief in biosimilars primarily based in Switzerland.

Strengthening foundations – ESG
Aiming to proceed strengthening the foundations of its enterprise together with enhancing broad entry to innovation for sufferers, Novartis outlined key parts of its method to ESG. These embody making certain entry methods are integrated in all new product launches and rising the range of sufferers in medical trials, in addition to making certain revolutionary medicines attain extra sufferers in low and center revenue international locations sooner; uncared for tropical ailments stay a spotlight for innovation. Novartis will proceed to prioritize its main place in third-party ESG scores and confirmed that its revolutionary sustainability linked bond targets are on monitor.

Disclaimer

This press launch accommodates forward-looking statements throughout the that means of the USA Personal Securities Litigation Reform Act of 1995. Ahead-looking statements can typically be recognized by phrases equivalent to “technique,” “aspiration,” “goals,” “enhancing,” “ambition,” “potential,” “can,” “will,” “plan,” “might,” “may,” “would,” “count on,” “anticipate,” “search,” “look ahead,” “imagine,” “dedicated,” “investigational,” “pipeline,” “launch,” or comparable phrases, or by categorical or implied discussions concerning potential advertising and marketing approvals, new indications or labeling for the investigational or authorized merchandise described on this press launch; concerning potential future revenues from such merchandise; concerning the potential completion of the proposed spin-off of Sandoz; concerning the longer term industrial efficiency of Novartis or of Sandoz; concerning potential strategic advantages, synergies or alternatives from the proposed spin-off; concerning our expectations of an enhancing monetary profile; concerning management throughout key know-how platforms; or concerning potential future progress in key geographies. You shouldn’t place undue reliance on these statements. Such forward-looking statements are primarily based on our present beliefs and expectations concerning future occasions, and are topic to vital recognized and unknown dangers and uncertainties. Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might differ materially from these set forth within the forward-looking statements. There might be no assure that the investigational or authorized merchandise described on this press launch will probably be submitted or authorized on the market or for any further indications or labeling in any market, or at any specific time. Nor can there be any assure that suchproducts will probably be commercially profitable sooner or later. Neither can there be any assure that the proposed spin-off will probably be accomplished within the anticipated kind or throughout the anticipated time-frame or in any respect. Nor can there be any assure that we can enhance our monetary profile. Neither can there be any assure that we are going to obtain a management function throughout key know-how platforms or obtain progress in key geographies. Particularly, our expectations concerning our merchandise may very well be affected by, amongst different issues, the uncertainties inherent in analysis and growth, together with medical trial outcomes and extra evaluation of current medical information; an surprising failure to finish, or surprising delays in finishing, the proposed spin-off of Sandoz; an surprising failure or delay in realizing the potential strategic advantages, synergies or alternatives from the proposed spin-off; regulatory actions or delays or authorities regulation typically; a failure to enhance our monetary profile; a failure to attain a management function throughout key know-how platforms or obtain progress in key geographies; international tendencies towards well being care value containment, together with authorities, payor and normal public pricing and reimbursement pressures and necessities for elevated pricing transparency; our means to acquire or preserve proprietary mental property safety; the actual prescribing preferences of physicians and sufferers; normal political, financial and enterprise circumstances, together with the consequences of and efforts to mitigate pandemic ailments equivalent to COVID-19; security, high quality, information integrity or manufacturing points; potential or precise information safety and information privateness breaches, or disruptions of our info know-how techniques, and different dangers and elements referred to in Novartis AG’s present Type 20-F on file with the US Securities and Change Fee. Novartis is offering the knowledge on this press launch as of this date and doesn’t undertake any obligation to replace any forward-looking statements contained on this press launch on account of new info, future occasions or in any other case.

About Novartis

Novartis is reimagining medication to enhance and prolong folks’s lives. As a number one international medicines firm, we use revolutionary science and digital applied sciences to create transformative remedies in areas of nice medical want. In our quest to search out new medicines, we constantly rank among the many world’s high firms investing in analysis and growth. Novartis merchandise attain practically 800 million folks globally and we’re discovering revolutionary methods to develop entry to our newest remedies. About 108,000 folks of greater than 140 nationalities work at Novartis world wide. Discover out extra at https://www.novartis.com.

Novartis is on Twitter. Signal as much as comply with @Novartis at https://twitter.com/novartisnews 
For Novartis multimedia content material, please go to https://www.novartis.com/information/media-library
For questions concerning the website or required registration, please contact [email protected] 

¹ Primarily based on IQVIA product sales for mixed generics and biosimilars market, referring to March 2022

# # #

Novartis Media Relations
E-mail: [email protected] 

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]